Ultragenyx Pharmaceutical Inc. (RARE) is a Healthcare stock tracked by StreetAlpha. It last closed at $14.60 on Oct 5, down 1.14% on the day. RARE reports earnings on Tue, Nov 3, 2026. The average 12-month price target from 15 analysts is $26.73 (+83.1% from the last close), with a high of $39.00 and a low of $16.00. Analyst consensus is Buy, based on the latest ratings from 15 firms (9 buy, 6 hold, 0 sell). Over the past 90 days StreetAlpha recorded 4 whale options trades in RARE, 75% of them bullish and 25% bearish.
Each firm's latest rating on RARE in the past 90 days
Average 12-month target
$26.73
▲ 83.1% upside
Based on 15 analysts who set a price target on RARE in the past 90 days. The average target is $26.73, with a high of $39.00 and a low of $16.00, compared with the last close of $14.60.
Highest target$39.00
Average target$26.73
Lowest target$16.00
Latest rating changes
Evercore ISI GroupTarget raised
Sep 21Hold$16 → $18
BarclaysTarget raised
Sep 21Buy$32 → $35
Morgan StanleyMaintained
Sep 18Hold$20
CitigroupTarget raised
Sep 18Buy$28 → $32
Canaccord GenuityTarget raised
Sep 18Buy$37 → $39
Date
Firm
Action
Rating
Price target
Sep 21
Evercore ISI Group
Target raised
Hold
$16 → $18
Sep 21
Barclays
Target raised
Buy
$32 → $35
Sep 18
Morgan Stanley
Maintained
Hold
$20
Sep 18
Citigroup
Target raised
Buy
$28 → $32
Sep 18
Canaccord Genuity
Target raised
Buy
$37 → $39
Loading…
Whale Options Flow
90D
Total alerts
4
Bullish
3
75%
Bearish
1
25%
Date span
Jul 20 – Sep 23
Loading…
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RARE is in one of them and how their past RARE trades turned out.
